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Background: The use of intravenous contrast media (CM) has 
increased for the diagnosis of several diseases. The newly 
developed low osmolar nonionic contrast agents cause 
significantly decreased adverse reactions than the higher 
osmolar ones. However, adverse reactions may still occur, 
ranging in severity from minor side effects to severe 
complications. However, there have been few reports about 
cutaneous adverse reactions (CARs) to nonionic monomer 
CM. Objective: The purpose of this study was to evaluate 
clinical features of CAR to intravenous nonionic monomer 
CM. Methods: A total 47,338 examinees underwent intra-
venous iodinated contrast-enhanced computed tomography  
scan using nonionic monomer CM. Among the adverse 
reactions to the CM, we divided them into cutaneous or 
noncutaneous and immediate (＜1 hr) or late (≥1 hr) adverse 
reactions. Results: Adverse reactions were noted in 62 cases 
out of the total 47,338 cases; 50 cases (80.7%) were 
categorized CARs. Among them, there were 24 male and 26 
female patients. There was no significant difference between 
the sexes, and CARs occurred in all age groups. The highest 
occurrence was in the age range of 50∼59 years. CARs 
included urticaria (78%), angioedema (10%), maculo-
papular rash (8%), erythema (2%), and pruritus without rash 
(2%). Immediate reactions were 92% (46 cases), while late 
reactions were 8% (4 cases). Conclusion: CARs to nonionic 
monomer CM accounted for most of the adverse reactions 
(80.7%) and urticaria was the most common. (Ann Dermatol 
24(1) 22∼25, 2012)
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INTRODUCTION
Imaging modality using contrast media (CM) is increasing. 
Adverse reactions to CM range from a mild inconvenience, 
such as nausea, vomiting, flushing, and pruritus, to life- 
threatening hypotension, anaphylactoid reaction, Stevens- 
Johnson syndrome, and toxic epidermal necrolysis
1,2. The 
adverse reactions occurring after CM administration may 
be divided into three different types: allergic and non-aller-
gic hypersensitivity reactions, toxic reactions and events 
unrelated to CM exposure
3. The CM maybe divided into 
higher osmolar, ionic agent and lower osmolar, nonionic 
agent. The former dissociate into ions when dissolved in 
water and are contained in an iodinated benzene ring
4. As 
a result, ionic agents have a higher osmolarity than blood, 
and the latter is less likely to cause adverse reaction
5-8. To 
date there has been research conducted on the adverse 
reactions of CM, but studies on cutaneous adverse reac-
tion (CAR) are rare. Here, we report results for CARs due 
to nonionic monomer CM, and hope to provide useful 
data for patient care and clinical research.Cutaneous Adverse Reactions to Nonionic Contrast Media
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Table 1. Age distribution of CARs to nonionic CM
Age (yr)
Cutaneous adverse reactions by sex Overall rage 
(No) Male (No) Female (No)
10∼19 0 1 1
20∼29 1 3 4
30∼39 4 1 5
40∼49 2 6 8
50∼59 7 10 17
60∼69 4 4 8
70∼79 5 1 6
＞80 1 0 1
Total 24 26 50
CARs: cutaneous adverse reactions, CM: contrast media, No: 
number.
Table 2. Past medical history of the 50 patients with CARs to 
nonionic monomer CM
Past medical history Number
Malignant neoplasm 17
Hypertension 13
Diabetus Mellitus 6
Allergic history 5
  Atopic dermatitis 2
  Food reaction 1
  D r u g  r e a c t i o n 1
  Chronic urticaria 1
Renal disease 5
Past adverse reactions to CM 3
Tuberculosis 3
Hepatitis 2
Asthma 0
CARs: cutaneous adverse reactions, CM: contrast media.
MATERIALS AND METHODS
Materials
We studied 50 CAR cases that were reported by patients 
or perceived by computed tomography (CT) radiological 
staff using nonionic monomer CM for CT scan between 
August 2005 and November 2009. We investigated 
adverse reactions in nature and gender difference through 
medical records and telephone contacts. 
The CM that causes adverse reactions includes nonionic 
monomer including Iomeprol (Iomeron, Ilsung pharma-
ceuticals CO., Seoul, Korea), Iopamidol (Iopamiro, Ilsung 
pharmaceuticals CO.), Iopromide (Ultravist, Bayerin 
Korea), Ioversol (Optiray, Mallinckrodt, St. Louis, MO, 
USA). 
Methods
1) Types and severity of adverse reactions of CM
The adverse reactions to nonionic monomer CM are clas-
sified into cutaneous, respiratory, cardiovascular, gastroin-
testinal symptoms
2. We defined the immediate reactions 
which occur within 1 hour after CM administration, and 
the delayed reactions which occur more than 1 hour after 
injection
2,3,9. The severity of the reaction was classified 
into mild and severe, and severe adverse reactions were 
defined as one or any combination of the following sym-
ptoms: dizziness, severe generalized urticaria, hypoten-
sion, laryngeal edema, and facial edema
10.
2) Statistics
The results of the study were analyzed statistically by chi 
square test using Statistical Package for the Social Sciences 
(SPSS) version 12.0 for Windows (SPSS Inc., Chicago, IL, 
USA). All statistical significance levels of differences were 
less than 0.05. 
RESULTS
Adverse reactions and clinical manifestation
From August 2005 to November 2009, a total 47,338 exa-
minees (27,733 male, 19,615 female) underwent intraven-
ous iodinated contrast-enhanced CT scans using nonionic 
monomer CM. Age distribution varied from 0 to over 80 
years. Of the total 47,338 examinees, 62 experienced 
adverse hypersensitivity reactions. Among them, 50 cases 
(80.7%) were categorized into CARs. Other symptoms 
included dizziness (n=10), hypotension (n=6), vomiting 
(n=6), dyspnea (n=4), chest pain (n=3), headache (n=2), 
perspiration (n=2), rhinorrhea (n=1), nasal congestion 
(n=1), cough (n=1), palpitation (n=1), anxiety (n=1), 
chill (n=1), and nausea (n=1). Severe adverse reactions 
such as dizziness, severe generalized urticaria, hypoten-
sion, and facial edema occurred in 16 cases, which 
accounted for 25.8% of all 62 cases of adverse reactions. 
General characteristics of CARs
CARs occurred in 24 men and 26 women, wth an age 
range from 18 to 81 and the 50’s showed highest inci-
dence, making the average age 51.5 (Table 1). On past 
medical history, a total of 17 cases of CAR combined with 
malignant neoplasm: colon cancer (n=6), stomach cancer 
(n=3), kidney cancer (n=3) and other cancer. Five aller-
gic history including atopic dermatitis (n=2), food allergy 
(n=1), drug allergy (n=1) and chronic urticaria (n=1) was 
accompanied by CARs. Three of CAR patients had past 
previous history of contrast adverse reaction. Other than 
that, hypertension (n=13), diabetes mellitus (n=6), 
kidney disease (n=5), tuberculosis (n=3), liver cirrhosis 
(n=3), hepatitis (n=2) combined with CARs, and asthma KE Jung, et al
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Table 3. Immediate and delayed CARs to nonionic monomer
CM
Immedeate No (%) Delayed No (%)
 Urticaria 39 (78) Maculopapular rash 4 (8)
 Angioedema  5 (10)
 Erythema  1 (2)
 Pruritus without rash  1 (2)
 Total 46 (92) 4 (8)
CARs: cutaneous adverse reactions, CM: contrast media, No: 
number.
was not included in those cases (Table 2).
CARs and clinical manifestation
Forty-six cases (92%) of CAR were immediate hypersen-
sitivity reactions including 39 cases (78%) of urticaria, 5 
cases (10%) of angioedema, 1 case (2%) of erythema, 1 
case (2%) of pruritus without rash. Delayed type hypersen-
sitivity accounted for 4 cases (8%), presenting maculopa-
pular rash (Table 3).
Treatment and progress
Seven cases were resolved spontaneously, and some were 
resolved after oxygen infusion (n=1), hydration (n=10), 
oxygen and hydration (n=1), Pheniramine injection (n= 
16), oral antihistamine (n=2), Pheniramine and dexame-
thasone or dexamethasone alone (n=23), combining epi-
nephrine (n=2).
DISCUSSION
In the past, we had frequent adverse reactions and poor 
radiographic imaging due to using hyperosmolar ionic 
CM. However, the adverse reaction decreased following 
the introduction of low osmolar CM, which was achieved 
by converting tri-iodinated benzoic acid into a nonionic 
molecule by replacing the carboxylic acid radical with an 
amide in the 1970s
11.
Skin eruption was known as the most common adverse 
reaction of nonionic CM. In studies of Mortelé et al.
7, 
among 545 hypersensitivity cases, 286 were urticaria, 131 
were pruritus, 114 were rash, 7 were associated with 
severe responses. Therefore a total of 538 CARs (98.7% of 
all hypersensitivity reactions) were reported, which was 
higher than the result of current study (80.7%; 50 out of 
62 cases).
There was no gender difference for CARs in this study, 
which was similar to the Wendt-Nordahl et al.
12 result 
where they investigated CARs after using nonionic CM for 
intravenous urography.
Adverse hypersensitivity reactions mainly occurred in 20 
to 50 year old patients, as like drug hypersensitivity 
reactions for they have vigorous immune function. In our 
study, incidence of CARs was higher for 20 to 50 year old 
patients than for other age groups (p＜0.05).
Delayed-type hypersensitivity reactions have been repor-
ted ranging from 0.52% to 9%
13-15, because it is difficult to 
correlate the relationship between the symptoms and 
usage of CM after a certain amount of time has passed. 
More than 50% of the delayed type hypersensitivity reac-
tion includes maculopapular rash, but because some in-
clude lethal responses such as Stevens-Johnson syndrome 
and toxic epidermal necrolysis, careful attention of the 
delayed type reaction is necessary after the use of CM 
even if there is no immediate hypersensitivity reaction. 
This study included 4 cases of maculopapular rash out of 
47,338 cases which did not show immediate symptoms, 
therefore the patient may not have recognized it as a 
hypersensitivity reaction caused by CM, and because the 
mild symptoms resolved spontaneously it may have been 
missed from the record.
The pathogenesis of hypersensitivity caused by CM is 
known to be related to drug reactions or non-immunologic 
mechanisms. Immediate type was proved to be related to 
histamines from mast cells by Laroche et al.
16, and that IgE 
related responses may explain the pathogenesis of contrast 
hypersensitivity
17,18. The delayed type is clinically similar 
to the T-cell mediated drug eruption, and by looking at 
lymphocytic infiltrations after the biopsy of skin lesions, 
skin reaction tests and patch tests, the relationship between 
the reaction and T-cell is now recognized
19-21. Still, the ex-
act pathogenesis of hypersensitivity caused by CM is not 
known, and therefore further study is needed to prove it.
There is a report that shows the hypersensitivity caused by 
CM can be reduced by using corticosteroid prior to the 
use of CM by Lasser et al.
22 and Greenberger et al.
23. On 
the other hand, Wolf et al.
24 suggested that the use of 
corticosteroid to reduce the rate of hypersensitivity caused 
by CM is not yet proven. However, when the patient has 
prior history of systemic hypersensitivity to CM and when 
it is not in a very urgent state, using the steroid before CM 
infusion may help in reducing the hypersensitivity of CM, 
provided the patient is not in a contraindication state of 
using the steroid
25-27.
In Conclusion, Based on 50 cases of CARs to nonionic 
CM from August 2005 to November 2009, we have come 
to the following conclusion: there was no difference 
between the sexes. The incidence of CARs was higher 
among people in their 20’s to 50’s than for other ages, 
because their immune system function is more active than 
at other ages, and among them the 50’s showed highest 
incidence of hypersensitivity. Three among 50 people Cutaneous Adverse Reactions to Nonionic Contrast Media
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who showed CAR had previous adverse reaction to 
contrast material. CARs included 39 cases of urticaria 
(78%), 5 cases of angioedema (10%), 4 cases of 
maculopapular rash (8%), 1 case of erythema (2%), 1 case 
of pruritus (2%). A total of 46 cases (92%) showed 
immediate type reaction, while 4 cases (8%) showed 
delayed type reactions, presenting as maculopapular rash.
Because the study is retrograded in finding CARs among 
all hypersensitivity reactions due to nonionic CM, and 
because the result was reported via patients themselves 
and medical team in CT room, some patients such as 
those who had mild symptoms may have been excluded 
from the study. Therefore, in order to measure and analyze 
CAR due to CM more accurately, an anterograde study at 
a large scale is mandatory.
REFERENCES
1. Bush WH, Swanson DP. Acute reactions to intravascular 
contrast media: types, risk factors, recognition, and specific 
treatment. AJR Am J Roentgenol 1991;157:1153-1161.
2. Christiansen C, Pichler WJ, Skotland T. Delayed allergy-like 
reactions to X-ray contrast media: mechanistic considera-
tions. Eur Radiol 2000;10:1965-1975.
3. Brockow K, Christiansen C, Kanny G, Clément O, Barbaud 
A, Bircher A, et al; ENDA; EAACI interest group on drug 
hypersensitivity. Management of hypersensitivity reactions 
to iodinated contrast media. Allergy 2005;60:150-158.
4. Maddox TG. Adverse reactions to contrast material: recogni-
tion, prevention, and treatment. Am Fam Physician 2002;66: 
1229-1234.
5. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, 
Matsuura K. Adverse reactions to ionic and nonionic contrast 
media. A report from the Japanese Committee on the Safety 
of Contrast Media. Radiology 1990;175:621-628.
6. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events 
after IV administration of contrast media. AJR Am J Roentge-
nol 2001;176:1385-1388.
7. Mortelé KJ, Oliva MR, Ondategui S, Ros PR, Silverman SG. 
Universal use of nonionic iodinated contrast medium for CT: 
evaluation of safety in a large urban teaching hospital. AJR 
Am J Roentgenol 2005;184:31-34.
8. Wang CL, Cohan RH, Ellis JH, Caoili EM, Wang G, Francis 
IR. Frequency, outcome, and appropriateness of treatment of 
nonionic iodinated contrast media reactions. AJR Am J Roent-
genol 2008;191:409-415.
9. Meth MJ, Maibach HI. Current understanding of contrast 
media reactions and implications for clinical management. 
Drug Saf 2006;29:133-141.
10. Kim SS, Park CH, Park MJ, Choi SH, Kim YS, Park HW, et al. 
Adverse reactions to radio-contrast media in computed 
tomography (CT) in general population: incidence and cli-
nical features. Korean J Asthma Allergy Clin Immunol 2007; 
27:157-161. 
11. Morcos SK, Thomsen HS. Adverse reactions to iodinated 
contrast media. Eur Radiol 2001;11:1267-1275.
12. Wendt-Nordahl G, Rotert H, Trojan L, Michel MS, Peters CR, 
Alken P, et al. Intravenous contrast media in uroradiology: 
evaluation of safety and tolerability in almost 50,000 pati-
ents. Med Princ Pract 2006;15:358-361.
13. Pedersen SH, Svaland MG, Reiss AL, Andrew E. Late allergy- 
like reactions following vascular administration of radiogra-
phy contrast media. Acta Radiol 1998;39:344-348.
14. Hosoya T, Yamaguchi K, Akutsu T, Mitsuhashi Y, Kondo S, 
Sugai Y, et al. Delayed adverse reactions to iodinated contrast 
media and their risk factors. Radiat Med 2000;18:39-45.
15. Yoshikawa H. Late adverse reactions to nonionic contrast 
media. Radiology 1992;183:737-740.
16. Laroche D, Aimone-Gastin I, Dubois F, Huet H, Gérard P, et 
al. Mechanisms of severe, immediate reactions to iodinated 
contrast material. Radiology 1998;209:183-190.
17. Mita H, Tadokoro K, Akiyama K. Detection of IgE antibody 
to a radiocontrast medium. Allergy 1998;53:1133-1140.
18. Kvedariene V, Martins P, Rouanet L, Demoly P. Diagnosis of 
iodinated contrast media hypersensitivity: results of a 6-year 
period. Clin Exp Allergy 2006;36:1072-1077.
19. Brockow K, Becker EW, Worret WI, Ring J. Late skin test 
reactions to radiocontrast medium. J Allergy Clin Immunol 
1999;104:1107-1108.
20. Delgado-Jimenez Y, Perez-Gala S, Aragüés M, Sanchez-Perez 
J, Garcia-Diez A. Late skin reaction to iodixanol (Visipaque): 
clinical manifestations, patch test study, and histopatholo-
gical evaluation. Contact Dermatitis 2006;55:348-353.
21. Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler 
C, et al. T cell-mediated reactions to iodinated contrast 
media: evaluation by skin and lymphocyte activation tests. J 
Allergy Clin Immunol 2005;115:179-185.
22. Lasser EC, Berry CC, Talner LB, Santini LC, Lang EK, Gerber 
FH, et al. Pretreatment with corticosteroids to alleviate 
reactions to intravenous contrast material. N Engl J Med 
1987;317:845-849.
23. Greenberger P, Patterson R, Kelly J, Stevenson DD, Simon 
D, Lieberman P. Administration of radiographic contrast 
media in high-risk patients. Invest Radiol 1980;15(6 Suppl): 
S40-43.
24. Wolf GL, Mishkin MM, Roux SG, Halpern EF, Gottlieb J, 
Zimmerman J, et al. Comparison of the rates of adverse drug 
reactions. Ionic contrast agents, ionic agents combined with 
steroids, and nonionic agents. Invest Radiol 1991;26:404- 
410.
25. Thomsen HS, Bush WH Jr. Adverse effects of contrast media: 
incidence, prevention and management. Drug Saf 1998;19: 
313-324.
26. Lasser EC, Berry CC, Mishkin MM, Williamson B, Zheutlin 
N, Silverman JM. Pretreatment with corticosteroids to pre-
vent adverse reactions to nonionic contrast media. AJR Am J 
Roentgenol 1994;162:523-526.
27. Greenberger PA, Patterson R. The prevention of immediate 
generalized reactions to radiocontrast media in high-risk 
patients. J Allergy Clin Immunol 1991;87:867-872.